Tools

Search Clinical Trials

Search

2 result(s) found

Eosinophilic Esophagitis


A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Dupilumab in Adult Patients with Active Eosinophilic Esophagitis

The primary objective of the study is to assess the clinical efficacy of repeat subcutaneous (SC) doses of dupilumab, compared with placebo, to relieve symptoms in adult patients with active, moderate to severe eosinophilic esophagitis (EoE).

More

Hepatitis B


A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi center Study to Evaluate the Safety and Efficacy of GS-9620 in combination with Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects with Chronic Hepatitis B and who are currently not on Treatment

This is a randomized, double-blind, placebo-controlled, multicenter Phase 2 study to evaluate the safety and efficacy of administering either 1 mg, 2 mg or 4 mg of GS-9620 orally once a week (every 7 days) both in-clinic and at home for 12 doses (Weeks 0-11) in adult CHB subjects who are not currently on treatment for CHB.

Approximately 175 subjects will be randomized in a 1:2:2:2 ratio to one of the four treatment arms (A:B: C: D) for weekly dosing for a total of 12 doses. All subjects will also be treated with Tenofovir

Disoproxil Fumarate (TDF) 300 mg oral daily for 48 weeks. Randomization will be stratified by HBeAg status (positive vs. negative) and ALT (> vs. <19 IU/L for female; > vs. < 30 IU/L for male).

  • Treatment Arm A: 25 subjects administered TDF 300 mg oral daily + placebo orally once a week (every 7 days) for 12 doses
  • Treatment Arm B: 50 subjects administered TDF 300 mg oral daily + GS-9620 1 mg orally once a week every 7 days) for 12 doses
  • Treatment Arm C: 50 subjects administered TDF 300 mg oral daily +GS- 9620 2 mg orally once a week every 7 days) for 12 doses
  • Treatment Arm D: 50 subjects administered TDF 300 mg oral daily + GS-9620 4 mg orally once a week (every 7 days) for 12 doses

After Week 11, GS-9620/placebo will be discontinued. All subjects will continue receiving TDF and will be followed for 37 weeks (Week 48).

More